To print: Select File and then Print from your browser's menu

Title: Azithromycin Effective In Treatment Of Pelvic Inflammatory Disease

URL:

Int Med Res 2003;31:1:45-54.
04/07/2003 03:14:03 PM
By Harvey McConnell

Azithromycin, ether alone or in combination with metronidazole, is both a shorter and a simpler treatment option for management of patients with acute pelvic inflammatory disease (PID), British clinicians report. Dr C D Bevan and colleagues at the Department of Gynaecology, Weston General Hospital, Weston-super-Mare, England, carried out the study about the effectiveness of azithromycin, alone or with metronidazole, compared with two standard multi-drug regimens for the treatment of PID. Three hundred and nine women with diagnosed PID, confirmed laparoscopically in 74.8% of patients, received once-daily intravenous (IV) azithromycin 500 mg for one or two days, followed by once-daily azithromycin 250 mg orally, for a total of seven days alone, or with three-times-daily IV metronidazole 400 mg or 500 mg. This was followed by oral administration for a total of 12 to 14 days treatment. This treatment regimen was compared with either a combination of metronidazole, doxycycline, cefoxitin and probenecid; or a combination of doxycycline, amoxycillin/clavulanate, given at the standard recommended doses for up to 21 days. The researchers found that the rates of clinical success for azithromycin, alone (97.1%). or with metronidazole (98.1%), were comparable to those for the two comparative drug regimens (94.6%). In addition, the rates of eradication among the women of [Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma hominis and anaerobes were comparable for each of the treatment groups. Both azithromycin regimens were well tolerated.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.